← PTC THERAPEUTICS, INC. PTCT
Market Price
$71.66
Market Cap
$5.97B
P/E Ratio
9.21
Revenue (FY 2025)
↑114.5% YoY
$1.73B
3-Yr CAGR: 35.3%
Net Income
↑287.9% YoY
$682.64M
Net Margin: 39.4%
Free Cash Flow
↑715.1% YoY
$702.34M
FCF Yield: 11.76%
EPS (Diluted)
↑264.5% YoY
$7.78
Basic: $8.58
Return on Equity
Efficiency
N/A
ROA: 1,014.2%
⚡ N/A due to negative equity (share buybacks or other)
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (PTCT)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2021: Revenue YoY (+41.4%) is identical to Gross Profit YoY (+41.4%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
- FY 2022: Revenue YoY (+29.7%) is identical to Gross Profit YoY (+29.7%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
- FY 2023: Revenue YoY (+34.2%) is identical to Gross Profit YoY (+34.2%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
- FY 2024: Revenue YoY (-14.0%) is identical to Gross Profit YoY (-14.0%). Verify the underlying Revenue and Gross Profit values for FY 2024 and FY 2023.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $82.7M | — | $20.7M | $-142.1M | — | $-4.17 | — | $-103.6M | $-105.3M | — |
| FY 2017 | $194.4M | +135.0% | $189.8M | $-79.0M | +44.4% | $-2.02 | +51.6% | $-10.1M | $-13.2M | +87.5% |
| FY 2018 | $264.7M | +36.2% | $66.2M | $-128.1M | -62.1% | $-2.75 | -36.1% | $-27.6M | $-34.7M | -163.9% |
| FY 2019 | $307.0M | +16.0% | $294.8M | $-251.6M | -96.4% | $-4.27 | -55.3% | $-98.6M | $-112.4M | -223.6% |
| FY 2020 | $380.8M | +24.0% | $95.2M | $-438.2M | -74.2% | $-6.64 | -55.5% | $-194.1M | $-211.9M | -88.5% |
| FY 2021 | $538.6M | +41.4% | $134.6M | $-523.9M | -19.6% | $-7.43 | -11.9% | $-251.3M | $-279.5M | -31.9% |
| FY 2022 | $698.8M | +29.7% | $174.7M | $-559.0M | -6.7% | $-7.79 | -4.8% | $-356.7M | $-388.7M | -39.0% |
| FY 2023 | $937.8M | +34.2% | $234.5M | $-626.6M | -12.1% | $-8.37 | -7.4% | $-158.4M | $-186.9M | +51.9% |
| FY 2024 | $806.8M | -14.0% | $201.7M | $-363.3M | +42.0% | $-4.73 | +43.5% | $-107.7M | $-114.2M | +38.9% |
| FY 2025 | $1,730.7M | +114.5% | $866.9M | $682.6M | +287.9% | $7.78 | +264.5% | $711.2M | $702.3M | +715.1% |
Valuation
Market Price
$71.66
Market Cap
$5.97B
Enterprise Value
$5.56B
P/E Ratio
9.21
P/B Ratio
N/A
FCF Yield
11.76%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
50.09%
Operating Margin
50.09%
Net Margin
39.44%
Return on Equity (ROE)
N/A (Negative Equity)
Return on Assets (ROA)
1,014.19%
Asset Turnover
25.71x
Revenue 3-Yr CAGR
35.30%
Financial Health & Liquidity
Current Ratio
0.07
Cash Ratio
1.02
Debt / Equity
-2.792
Debt / Assets
8.517
Cash & Equivalents
$984.65M
Total Debt
$573.26M
Book Value / Share
$-2.48
Cash Flow Efficiency
Operating Cash Flow
$711.20M
Capital Expenditures (CapEx)
$8.86M
Free Cash Flow
$702.34M
OCF / Revenue
41.09%
FCF / Revenue
40.58%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$7.78
EPS (Basic)
$8.58
Dividends / Share
N/A
Book Value / Share
$-2.48
EPS YoY Growth
264.48%
Balance Sheet (FY 2025)
Total Assets
$67.31M
Total Liabilities
$968.43M
Stockholders' Equity
-$205.31M
Current Assets
$67.31M
Current Liabilities
$968.43M